Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Urothelial Carcinoma Treatment Market: By Treatment, By Distribution Channel and Region Forecast 2020-2031
Urothelial Carcinoma Treatment Market: By Treatment, By Distribution Channel and Region Forecast 2020-2031
Urothelial Carcinoma Treatment Market size was valued at US$ 5.5 billion in 2024 and is expected to reach US$ 20.6 billion by 2031, growing at a significant CAGR of 20.6% from 2025-2031. Urothelial carcinoma is also called transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is the most common type of bladder cancer of the ureter, urachus, and urethra. Urothelial cell carcinoma starts from the transitional epithelium. Potential signs of recognizing urothelial carcinoma include blood in urine, persistent back pain, and painful urination. Generally, urothelial cell carcinoma is diagnosed using blood tests and scanning. Treatment may include anticancer drugs, antibacterials to reduce or stop the growth of cancer cells, and other treatments such as radiotherapy or nephroureterectomy are indicated. The market growth is driven by the increase in the global prevalence rate of bladder cancer.
According to World Cancer Research Fund International, bladder cancer is the ninth most common cancer in the world, and in the year 2012 - 430,000 new cases were diagnosed. The market has many large players and actively developing and launching new products related to urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic A/S collaborated with F. Hoffman-La Roche Ltd to evaluate the Tecentriq and CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline drugs for the treatment of urothelial carcinoma such as B-701 (in phase 2 clinical trials by BioClin Therapeutics, and FGFR-3 Antibody (By Eli Lilly and Company in phase 1 clinical trials) are expected to boost future revenue forecasts.
Study Period
2025-2031Base Year
2024CAGR
20.6%Largest Market
North-AmericaFastest Growing Market
North-America
The market is driven by the increase in global prevalence of the bladder cancer and emergence of potential diagnostics for identifying bladder cancer. Furthermore, increase funding for R&D activities to develop new cancer therapies and growing awareness regarding early diagnosis of cancer as a result of awareness programs or other initiatives by government and non-government organizations are expected to boost the market over the forecast period. However, high cost of R&D for development of new drugs and presence of generic drugs in the market are expected to hamper the market revenue growth during the forecast period.
Geographically, market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America expected to grow at significant rates owing to growing prevalence of bladder cancer, increase in awareness and well-established healthcare infrastructure. American Cancer Society estimates that, about 79,030 new cases of bladder cancer in 2017 in U.S. alone. Europe region expected to grow at notable rates owing to the factors such as growing awareness related to early diagnosis of cancer and developed healthcare infrastructure coupled with prevalence rates of urothelial cancer. Asia Pacific region is expected exhibit significant growth opportunity owing to developing healthcare infrastructure and low R&D costs.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 5.5 billion |
|
Market Size in 2031 |
US$ 20.6 billion |
|
Market CAGR |
20.6% |
|
By Treatment |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Urothelial Carcinoma Treatment Market size was valued at US$ 5.5 billion in 2024 and is expected to reach US$ 20.6 billion by 2031, growing at a significant CAGR of 20.6% from 2025-2031.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The market key players are: GlaxoSmithKline plc (U.K.), Genentech, Inc. (U.S.), Novartis AG (Switzerland), Dendreon (U.S.), Merck KGaA (Germany)
| 1.Executive Summary |
| 2.Global Urothelial Carcinoma Treatment Market Introduction |
| 2.1.Global Urothelial Carcinoma Treatment Market - Taxonomy |
| 2.2.Global Urothelial Carcinoma Treatment Market - Definitions |
| 2.2.1. By Treatment |
| 2.2.2. By Distribution Channel |
| 2.2.3. By Region |
| 3.Global Urothelial Carcinoma Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Urothelial Carcinoma Treatment Market Analysis, 2020-2024 and Forecast 2025-2031 |
| 4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Urothelial Carcinoma Treatment Market By Treatment, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 5.1. Immunotherapy |
| 5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Radiotherapy |
| 5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Chemotherapy |
| 5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Urothelial Carcinoma Treatment Market By Distribution Channel, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Urothelial Carcinoma Treatment Market By Region, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Urothelial Carcinoma Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 8.1. Treatment Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Immunotherapy |
| 8.1.2.Radiotherapy |
| 8.1.3.Chemotherapy |
| 8.1.4.Others |
| 8.2. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Retail Pharmacies |
| 8.2.3.Others |
| 8.3. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Urothelial Carcinoma Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 9.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Immunotherapy |
| 9.1.2.Radiotherapy |
| 9.1.3.Chemotherapy |
| 9.1.4.Others |
| 9.2. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Retail Pharmacies |
| 9.2.3.Others |
| 9.3. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Urothelial Carcinoma Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 10.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Immunotherapy |
| 10.1.2.Radiotherapy |
| 10.1.3.Chemotherapy |
| 10.1.4.Others |
| 10.2. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Retail Pharmacies |
| 10.2.3.Others |
| 10.3. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Urothelial Carcinoma Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Immunotherapy |
| 11.1.2.Radiotherapy |
| 11.1.3.Chemotherapy |
| 11.1.4.Others |
| 11.2. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Retail Pharmacies |
| 11.2.3.Others |
| 11.3. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Urothelial Carcinoma Treatment Market ,2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Immunotherapy |
| 12.1.2.Radiotherapy |
| 12.1.3.Chemotherapy |
| 12.1.4.Others |
| 12.2. Distribution Channel Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Retail Pharmacies |
| 12.2.3.Others |
| 12.3. Country Analysis 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.GlaxoSmithKline plc (U.K.) |
| 13.2.2.Genentech, Inc. (U.S.) |
| 13.2.3.Novartis AG (Switzerland) |
| 13.2.4.Dendreon (U.S.) |
| 13.2.5.Merck KGaA (Germany) |
| 13.2.6.Eisai Co. (Japan) |
| 13.2.7.Sanofi S.A. (France) |
| 13.2.8.Bristol-Myers Squibb (U.S.) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.